Elsevier MDL Offers Free Trial of Breakthrough Chemical Drawing Tool, MDL® Draw
Innovative capabilities, high-quality graphics and cost savings offer scientists clear advantages
San Ramon, CA - March 22, 2007 - Elsevier MDL is offering a free 30-day evaluation of the new-generation MDL® Draw chemical drawing tool so researchers can experience for themselves the innovative capabilities and qualities that make MDL Draw a superior solution with dramatic advantages in efficiency, quality and value.
"MDL Draw is a bold step forward in chemical drawing," said Trevor Heritage, Senior Vice President and Chief Scientific Officer, Elsevier MDL. "Now researchers can test drive it and in a few minutes learn why leading pharma companies are adopting MDL Draw as their single drawing package enterprise-wide."
MDL Draw lets scientists rapidly create images for presentations, reports and scientific papers. MDL Draw is compatible with MDL® ISIS/Draw images and can be used with ISlS applications, allowing researchers to combine the power of MDL Draw with their existing applications and documents.
With MDL Draw, scientists can use dynamic templates to create complex reactions and structures with one click. They can rapidly draw structures freehand, including bonds, rings, chains and atoms, without switching back and forth between tools. And scientists can annotate reaction schemes with text and arrows, and apply font, color and line thickness changes with just a few clicks from the convenient formatting toolbar.
MDL Draw serves a broad range of scientists. Premier MDL chemical representation supports sophisticated chemistry, and biomolecule drawing allows biochemists to create and import 1- and 3-letter peptides, DNA or RNA. Using the sequence tool, scientists can draw crossing bonds, disulfide bridges and attach side-chain protecting groups.
For organizations, MDL Draw Enterprise Edition offers programming flexibility. Developers can easily add MDL Draw as the structure editing and rendering tool for custom applications. MDL Draw offers a flexible add-in capability that enables you to build in and add customized menu items for scientific calculators, property and spectral prediction tools, library enumeration, file format interconversion, including InChi, and name to structure converters.
For more information about MDL Draw, to register for a free evaluation copy, or to sign up for free Webinar, visit www.mdl.com.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com.
Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Senior Director, Marketing & Communications
Phone: +1 925 543-5400